Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy

Journal of the National Cancer Institute

Volumn 105, Issue 5, 2013, Pages 321-333

  Marinovich, Michael L ^a   Houssami, Nehmat ^a   MacAskill, Petra ^a   Sardanelli, Francesco ^b,c   Irwig, Les ^a   Mamounas, Eleftherios P ^d   Von Minckwitz, Gunter ^e   Brennan, Meagan E ^a   Ciatto, Stefano ^f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d Aultman Health Foundation   (United States)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f APSS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; ODDS RATIO; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAXOIDS;

EID: 84874855647     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs528     Document Type: Article

References (71)

1. Makhoul I, Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol. 2011;103(4):348-357.
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-2685.
3. Von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol. 2001;19(15):3506-3515.
4. Von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100(8):552-562.
5. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940-1949.
6. Kaufmann M, Von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(12):1927-1934.
7. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86(7):1041-1046.
8. Montagna E, Bagnardi V, Rotmensz N, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124(3):689-699.
9. Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296-1316.
10. Heys SD, Chaturvedi S. Primary chemotherapy in breast cancer: the beginning of the end or the end of the beginning for the surgical oncologist? World J Surg Oncol. 2003;1.
11. Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011;378(9805):1804-1811.
12. DeMartini WB, Lehman CD, Peacock S, Russell MT. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy. Academic Radiol. 2005;12(7):806-814.
13. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3.
14. Whiting PF, Weswood ME, Rutjes AWS, Reitsma JB, Bossuyt PNM, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6.
15. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865-2884.
16. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129-1135.
17. SAS Institute. SAS/STAT User's Guide. Version 8. Cary, NC: SAS Institute; 1999.
18. Macaskill P. Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol. 2004;57(9):925-932.
19. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C, eds. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 1.0. The Cochrane Collaboration; 2010:1-61.
20. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21(9):1237-1256.
21. Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2010;257(1):56-63.
22. Hsiang DJ, Yamamoto M, Mehta RS, et al. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Arch Surg. 2007;142(9):855-860.
23. Chen JH, Mehta RS, Nalcioglu O, Su MY. Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response? Ann Surg Oncol. 2008;15(12):3609-3613.
24. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112(1):17-26.
25. Baek HM, Chen JH, Nie K, et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology. 2009;251(3):653-662.
26. Bahri S, Chen JH, Mehta RS, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol. 2009;16(6):1619-1628.
27. Straver ME, Loo CE, Rutgers EJT, et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010;251(4):701-707.
28. Warren RML, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004;90(7):1349-1360.
29. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat. 2002;72(2):145-152.
30. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kuhn T. Breast MRI for monitoring response of primary breast cancer to neoadjuvant chemotherapy. Eur Radiol. 2002;12(7):1711-1719.
31. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol. 2005;184(3):868-877.
32. Bodini M, Berruti A, Bottini A, et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat. 2004;85(3):211-218.
33. Fangberget A, Nilsen LB, Hole KH, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol. 2011;21(6):1188-1199.
34. Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23(12):2676-2685.
35. Murata Y, Kubota K, Hamada N, et al. Diffusion-weighted magnetic resonance imaging for assessment after neoadjuvant chemotherapy in breast cancer, based on morphological concepts. Oncol Lett. 2010;1(2):293-298.
36. Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2008;98(2):289-293.
37. Nakamura S, Ishiyama M, Tsunoda-Shimizu H. Magnetic resonance mammography has limited ability to estimate pathological complete remission after primary chemotherapy or radiofrequency ablation therapy. Breast Cancer. 2007;14(2):123-130.
38. Nicoletto MO, Nitti D, Pescarini L, et al. Correlation between magnetic resonance imaging and histopathological tumor response after neoadjuvant chemotherapy in breast cancer. Tumori. 2008;94(4):481-488.
39. Belli P, Romani M, Costantini M, et al. Role of magnetic resonance imaging in the pre and postchemotherapy evaluation in locally advanced breast carcinoma. Rays. 2002;27(4):279-290.
40. Belli P, Costantini M, Malaspina C, Magistrelli A, LaTorre G, Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol. 2006;61(11):946-953.
41. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: Noninvasive monitoring with functional MR imaging - pilot study. Radiology. 2003;228(1):63-69.
42. Corcioni B, Santilli L, Quercia S, et al. Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapy. J Ultrasound. 2008;11(4):143-150.
43. Wright FC, Zubovits J, Gardner S, et al. Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer - clinical examination, mammography, or magnetic resonance imaging? J Surg Oncol. 2010;101(7):604-610.
44. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol. 2003;181(5):1275-1282.
45. Choi JH, Lim HI, Lee SK, et al. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol. 2010;102(5):392-397.
46. Trecate G, Ceglia E, Stabile F, et al. Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathologic evaluation of residual disease. Tumori. 1999;85(4):220-228.
47. Moon HG, Han W, Lee JW, et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol. 2009;20(4):636-641.
48. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol. 2003;13(6):1213-1223.
49. Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996;78(1):91-100.
50. Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;92(3):231-238.
51. Garimella V, Qutob O, Fox JN, et al. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol. 2007;33(2):157-161
52. Cocquyt VF, Villeirs GM, Blondeel P, et al. Assessment of response to preoperative chemotherapy in patients with stage II and III breast cancer: the value of MRI. Breast. 2002;11(4):306-315.
53. Akazawa K, Tamaki Y, Taguchi T, et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2006;12(2):130-137.
54. Bollet MA, Thibault F, Bouillon K, et al. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study. Int J Radiat Oncol Biol Phys. 2007;69(1):13-18.
55. Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer. 2010;102(1):35-41.
56. Woodhams R, Kakita S, Hata H, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: Diffusion-weighted imaging - comparison with contrast-enhanced MR imaging and pathologic findings. Radiology. 2010;254(2):357-366.
57. Tozaki M, Uno S, Kobayashi T, et al. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI. Radiat Med. 2004;22(4):246-253.
58. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol. 2002;179(5):1193-1199.
59. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat. 2004;83(1):67-76.
60. Armitage P, Behrenbruch C, Brady M, Moore N. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Med Image Anal. 2005;9(4):315-329.
61. Kwong MS, Chung GG, Horvath LJ, et al. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J. 2006;12(3):212-221.
62. Montemurro F, Martincich L, De Rosa G, et al. Dynamic contrastenhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol. 2005;15(6):1224-1233.
63. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14(8):1371-1379.
64. Drew PJ, Kerin MJ, Mahapatra T, et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 2001;27(7):617-620.
65. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320-327.
66. Yuan Y, Chen XS, Liu SY, Shen KW. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. Am J Roentgenol. 2010;195(1):260-268.
67. Berg WA, Madsen KS, Schilling K, et al. Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology. 2010;258(1):59-72.
68. Turnbull LW. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed. 2009;22(1):28-39.
69. Von Minckwitz G, Kaufmann M, Kummel S, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Results from the German neoadjuvant trials meta-analysis. J Clin Oncol. 2012;30 (15):1796-1804.
70. Marinovich ML, Sardanelli F, Ciatto S, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21(5):669-677.
71. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol. 2008;26(19):3248-3258.